Revolution Medicines
700 Saginaw Drive
Redwood City
California
94063
United States
109 articles about Revolution Medicines
-
In April Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. This morning Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
-
Revolution Medicines Raises Another $56 Million and Completes Pivot from Antifungal to Cancer Com...
4/24/2018
Revolution Medicines closed on a Series B financing round worth $56 million. The round was led by Nextech Invest, with participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and undisclosed institutional investors. -
REVOLUTION Medicines Raises $56 Million Series B Financing
4/24/2018
REVOLUTION Medicines, Inc. announced it has raised $56 million in a Series B financing to support its ongoing R&D programs and general business activities.
-
Revolution Medicines Appoints Vincent Miller, M.D. To Board Of Directors
10/6/2017
-
Revolution Medicines Appoints Cancer Leader Dr. Stephen Kelsey As President Of Research And Development
3/20/2017
-
Launched in 2015 with $45 Million, Bay Area Revolution Medicines Scores $25 Million
12/21/2016
-
Revolution Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., And Senior Advisor, Eric Gordon, Ph.D.
6/14/2016
-
Rationally Designed Antifungal Compounds That Evade Resistance Reported In Nature Chemical Biology By Scientific Founder Of Revolution Medicines
6/1/2015
-
Revolution Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson To Board Of Directors
4/9/2015